Orsini Healthcare

Based in the US, Orsini Healthcare provides specialized pharmacy solutions that focus on improving access to critical medications for patients with rare diseases and complex therapy requirements. Orsini Healthcare, founded in 1987 and headquartered in Elk Grove Village, US, specializes in pharmacy solutions catering to patients with rare diseases. The company was established by Michael Fieri, who has a history of founding other healthcare ventures. As of February 11, 2022, Orsini was acquired by Carlyle Group and Consonance Capital for an undisclosed sum, marking a significant evolution in its business strategy.

Orsini specializes in pharmacy solutions tailored for patients with rare diseases and complex therapy needs, focusing on simplifying access to essential medications. The company's primary offerings include specialty pharmacy services, home infusion and nursing, and third-party logistics, designed to facilitate connections between patients and necessary therapies. Core products include treatments for conditions like Duchenne Muscular Dystrophy, Idiopathic Pulmonary Fibrosis, and various genetic disorders, leveraging advanced therapies like cell and gene treatments. Orsini supports a diverse clientele, including patients, healthcare providers, biopharmaceutical companies, and payors, mainly in the United States, with key operations in Illinois and Ohio, and expanding nationally.

Orsini generates revenue through specialty pharmacy services and partnerships with biopharmaceutical companies. Transactions typically occur through direct partnerships where Orsini serves as an exclusive distributor for specific therapies, including Boehringer Ingelheim’s JASCAYD® (nerandomilast) and Ionis’ DAWNZERA™ (donidalorsen). The revenue model is centered on B2B transactions, with pharmaceutical manufacturers collaborating with Orsini to manage distribution and patient care. This framework allows for streamlined access to specialty medications, ensuring efficient delivery and support for patients with rare diseases, with revenue driven by prescription volumes and associated services.

In February 2022, Orsini Healthcare received investment from Carlyle Group and Consonance Capital, which will enable the company to expand patient access to therapies for rare diseases and chronic conditions. Future growth strategies include launching new products designed to enhance therapy options and targeting expansion into additional geographic markets to reach more patients. Specific timelines for these initiatives and products will be developed to align with the ongoing investment and operational capabilities.